Keratinocyte growth factor in Acute lung injury to REduce pulmonary dysfunction – a randomised placebo controlled trial (KARE)

Registry ID
EUCTR2010-021186-70
Source registry
EUCTR
Status
Completed
Phase
PHASE2
Sponsor
Belfast Health and Social Care Trust
Start date
2010-10-01
Completion date
2014-03-26
Last update
2026-08-16

Conditions

Summary

The aim of this study is to test the hypothesis that palifermin will be effective in the treatment of patients with acute lung injury (ALI). The trial objective is to undertaken a randomised double blind placebo controlled (i.e. dummy medication) clinical trial to study whether palifermin improves important surrogate markers of clinical outcome and is safe in adult patients with ALI in intensive care.

Locations

Related clinical trials

View on source registry